A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis

Acta Neurologica Belgica

Volumn 101, Issue 4, 2001, Pages 210-216

  Van De Wyngaert, F A ^a   Beguin, C ^a   D'Hooghe, M B ^b   Dooms, G ^a   Lissoir, F ^b   Carton, H ^b   Sindic, C J M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b National Multiple Sclerosis Center   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; CORTICOSTEROID; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT; METHYLENE BLUE; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG INFUSION; FATIGUE; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 0035707562     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet, 1988, ii : 179-183.
2. CURSIEFEN S., FLACKENEKER P., TOYKA K. V., RIECKMANN P. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive Multiple Sclerosis. Eur. Neurol., 2000, 43 : 186-187.
3. EDAN G., MILLER D., CLANET M., CONFAVREUX C., LYON-CAEN O. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis : A randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry, 1997, 62 : 112-118.
4. FIDLER J. M., DEJOY S. Q., GIBBONS J. J. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J. Immunol., 1986 a, 137 : 727-732.
5. FIDLER J. M., DEJOY S. Q., SMITH F. R., GIBBONS J. J. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Non specific adherent suppressor cells derived from mitoxantrone-treated mice. J. Immunol., 1986 b, 136 : 2747-2754.
6. FILIPPINI G., BRUSAFERRI F., SIBLEY W. A., CITTERIO A., CIUCCI G. et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. (Cochrane Review). In : The Cochrane Library, Issue 3, 2001. Oxford : Update Software.
7. GONSETTE R. E., DEMONTY L. Mitoxantrone : a new immunosuppressive agent in Multiple Sclerosis. In : Recent advances in Multiples Sclerosis Therapy. GONSETTE R. E., DELMOTTE P. (eds.). Elsevier, 1989, 161-164.
8. GOODKIN D. E., BAILLY R. C., TEETZEN M. L., HERTSGAARD D., BEATTY W. W. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991, 41 : 20-25.
9. GOODKIN D. E., RUDICK R. A., MEDENDORP S. V., DAUGHTRY M. M., SCWETZ K. M. et al. Low dose oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann.Neurol. 1995, 37 : 30-40.
10. HARTUNG H. P., GONSETTE R. and the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis (MS) : A placebo-controlled, randomized, observer-blind European phase III multicenter study-Clinical results. Multiple Sclerosis, 1998, 4 : 325.
11. KAPPOS L., PATZOLD U., DOMMASH D., POSER S., HAAS J. et al. Cyclosporine versus azathioprine in long-term treatment of multiple sclerosis-Results of the German multicenter study. Ann. Neurol., 1988, 23 : 56-63.
12. LEVINE S., SALTZMAN A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol., 1986, 13 : 175-181.
13. LUBLIN F. D., LAVASA M., VITI C., KNOBLER R. L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol., 1987, 45: 122-128.
14. MAUCH E., FETZER U., KRAPF H., LAUFEN H., KORNHUBER H.H. Treatment of Multiple Sclerosis with low-dose cyclophosphamide or mitoxantrone. In : Current concepts in Multiple sclerosis. WIETHÖLTER H. et al. (eds.). Elsevier, 1991 : 285-288.
15. MAUCH E., KORNHUBER H.H. KRAPF H., FETZER U., LAUFEN H. Treatment of Multiple Sclerosis with Mitoxantrone. Eur. Arch. Psychiatry Clin. Neurosci., 1992, 242 : 96-102.
16. MILLEFIORINI E., GASPERINI C., POZZILLI C., D'ANDREA F., BASTANIELLO S. et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis : 24-month clinical and MRI outcome. J. Neurol., 1997, 244 : 153-159.
17. POSER C. M., PATY D. N., SCHEINBERG L., MCDONALD W. I., DAVIS F. A. New diagnostic criteria for multiple sclerosis : guidelines for research protocols. Ann. Neurol., 1983, 13 : 227-231.
18. POUILLART P., MARAL J., PALANGIE T. La mitoxantrone-une nouvelle molécule anticancéreuse. Pharmacologie, efficacité et tolérance. Comptes Rendus Thérap. Pharmacol. Clin., 1987, 5 : 1-15.
19. RIDGE S. C., SLOBODA A. E., REYNOLDS R. A., LEVINE S., ORONSKY A. L. et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol., 1985, 35 : 35-42.
20. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The cooperative multiple sclerosis study group. Lancet, 1991, 337 : 441-446.
21. The Multiple Sclerosis Study Group. The efficacy and toxicity of cyclosporine A in chronic progressive multiple sclerosis : a randomized, double-blind, placebo-controlled clinical trial. Ann. Neurol., 1990, 27 : 591-605.
22. TROIANO R., COOK S., DOWLING P. Steroid therapy in multiple sclerosis. Point of view. Arch. Neurol., 1987, 44 : 803-807.
23. WEINER H. L., MACKIN G. A., ORAV E. J., HAFLER D. A., DAWSON D. M. et al. And the Northeast Cooperative Multiple Sclerosis Treatment Group. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Neurology, 1993, 43 : 910-918.